Success Metrics

Clinical Success Rate
85.7%

Based on 6 completed trials

Completion Rate
86%(6/7)
Active Trials
2(13%)
Results Posted
0%(0 trials)
Terminated
1(6%)

Phase Distribution

Ph not_applicable
4
25%
Ph phase_4
2
13%
Ph phase_2
2
13%
Ph phase_3
4
25%

Phase Distribution

0

Early Stage

2

Mid Stage

6

Late Stage

Phase Distribution12 total trials
Phase 2Efficacy & side effects
2(16.7%)
Phase 3Large-scale testing
4(33.3%)
Phase 4Post-market surveillance
2(16.7%)
N/ANon-phased studies
4(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

6 of 9 finished

Non-Completion Rate

33.3%

3 ended early

Currently Active

2

trials recruiting

Total Trials

16

all time

Status Distribution
Active(2)
Completed(6)
Terminated(3)
Other(5)

Detailed Status

Completed6
unknown5
Recruiting2
Withdrawn2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
16
Active
2
Success Rate
85.7%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (16.7%)
Phase 34 (33.3%)
Phase 42 (16.7%)
N/A4 (33.3%)

Trials by Status

terminated16%
completed638%
recruiting213%
unknown531%
withdrawn213%

Recent Activity

2 active trials
Showing 5 of 16
unknown

Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients

NCT05974410
recruitingnot_applicable

Potassium-Competitive Acid Blocker Versus Proton Pump Inhibitor as A Part of Bismuth Based Quadruple Therapy for Treatment of Helicobacter Pylori Infection

NCT07165444
completed

PROTon Pump Inhibitors and Stent OCclusion Rate Of Lumen Apposing Metal Stents

NCT05817721
completed

Nordic Gastric and Esophageal Tumor Study

NCT05688761
completed

Risk Factors and Machine Learning Model for Proton Pump Inhibitor Related Acute Kidney Injury

NCT05533619
View all 16 trials

Clinical Trials (16)

Showing 16 of 16 trials
NCT05974410

Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients

Unknown
NCT07165444Not Applicable

Potassium-Competitive Acid Blocker Versus Proton Pump Inhibitor as A Part of Bismuth Based Quadruple Therapy for Treatment of Helicobacter Pylori Infection

Recruiting
NCT05817721

PROTon Pump Inhibitors and Stent OCclusion Rate Of Lumen Apposing Metal Stents

Completed
NCT05688761

Nordic Gastric and Esophageal Tumor Study

Completed
NCT05533619

Risk Factors and Machine Learning Model for Proton Pump Inhibitor Related Acute Kidney Injury

Completed
NCT06121245Not Applicable

The PRO-SOma COla (PROSOCO) Study

Unknown
NCT04415983Phase 3

Study of Nitazoxanide (NTZ) for Helicobacter Pylori in Children

Recruiting
NCT02150447Phase 3

The Use of Proton Pump Inhibitor on the Prevention of Gastric Cancer Bleeding

Terminated
NCT02254889Not Applicable

Pain After Endoscopic Submucosal Dissection

Completed
NCT02039869Not Applicable

Confocal Endomicroscopy for Non-Erosive Reflux Disease (CE NERD)

Withdrawn
NCT02288078Phase 2

Oral Steroids for Regorafenib-induced Fatigue/Malaise in Unresectable mCRC (KSCC1402/HGCSG1402)

Unknown
NCT01742429Phase 4

Levofloxacin and Bismuth-containing Therapy Versus Quadruple Therapy as Second-line Treatment of Resistant Helicobacter Pylori Infection

Completed
NCT01668927Phase 4

Empirical Rescue Therapies of Helicobacter Pylori Infection

Completed
NCT00771706Phase 3

Longitudinal Study of Children With a Chronic Cough and the Impact of Gastroesophageal Reflux

Withdrawn
NCT00789061Phase 2

Applying Proton Pump Inhibitor to Prevent and Treat Acute Fluctuating Hearing Loss in Patients With SLC26A4 Mutation

Unknown
NCT00154440Phase 3

Helicobacter - Lymphoma - Radiation Part I: Eradication, Part II: Radiation

Unknown

All 16 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
16